Future studies should evaluate whether targeting WISP1 signaling, alone or in combination with endocrine or chemotherapy, counteracts therapy resistance and improves treatment outcomes in aggressive, hormone therapy-resistant breast cancer. This evidence concerns the gene CCN4 and breast carcinoma.